DAX-044 in Adults With Advanced Solid Tumours: a First-in-human Study of Safety, Dose and Early Anti-cancer Activity.
A Phase 1 First-in-human Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Anti-tumour Activity of Intravenous DAX-044 in Adults With Advanced Solid Tumours.
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety and tolerability of DAX-044 as monotherapy, and to determine its maximum tolerated dose, in adults with advanced solid tumours.
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Descrição detalhada
This is a first-in-human, multicentre, Phase 1, open-label study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), immunogenicity and anti-tumour activity of DAX-044, a targeted, potency-optimised interleukin-12 (IL-12) immunocytokine, as monotherapy in adults with advanced solid tumours.
Part 1 (dose escalation) will evaluate DAX-044 monotherapy across planned dose levels, using a Bayesian optimal interval (BOIN) design to determine the maximum tolerated dose (MTD). Participants with any of the eligible tumour types are enrolled together into dose-level cohorts. Each participant remains at their allocated dose level; escalation occurs between cohorts only. Additional participants may be enrolled into backfill cohorts at dose levels already cleared for safety.
Part 2 (dose expansion) will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts.
In both parts, DAX-044 is given by intravenous infusion on Day 1 of each 21-day cycle, until disease progression, unacceptable toxicity, withdrawal of consent or sponsor termination, to a maximum of 24 months.
Tipo de estudo
Tipo de estudo
Inscrição (Estimado)
Inscrição
Estágio
Estágio
- Fase 1
Contactos e Locais
Contato de estudo
Contato de estudo
- Nome: Iva Nikolic
- Número de telefone: +61 3 9067 5625
- E-mail: clinops@audax.bio
Estude backup de contato
- Nome: Joanne Yan
- Número de telefone: +61 3 9067 5625
- E-mail: clinops@audax.bio
Locais de estudo
-
-
Western Australia
-
Nedlands, Western Australia, Austrália, 6009
- Linear Clinical Research Ltd
-
Contato:
- Desi du Plessis
- Número de telefone: +61 8 63825100
- E-mail: actcstartup@linear.org.au
-
Investigador principal:
- Timothy Guy Humphries
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Aged at least 18 years.
- Histologically or cytologically confirmed locally advanced or metastatic non-small cell lung cancer, gastric or gastro-oesophageal junction adenocarcinoma, squamous cell carcinoma of the head and neck, melanoma other than ocular or uveal, triple-negative breast cancer, castrate-resistant prostate cancer (CRPC), microsatellite stable colorectal cancer, pancreatic ductal adenocarcinoma, or epithelial ovarian cancer. Tumour-type-specific requirements for prior therapy also apply.
- Measurable disease by RECIST v 1.1, except CRPC, which may be measurable or non-measurable.
- At least 1 prior line of systemic standard-of-care therapy, with radiographic progression on or after the last line received. CRPC with non-measurable disease must instead show progression of PSA.
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Life expectancy greater than 3 months.
- Able to provide pre-treatment tumour tissue, either archival or as a fresh biopsy.
- Adequate organ function within 14 days before first dose, including absolute neutrophil count greater than or equal to 1.5 x 10^9/L, platelets greater than or equal to 100 x 10^9/L, haemoglobin greater than or equal to 9 g/dL, bilirubin less than or equal to 1.5 times the upper limit of normal (ULN), transaminases less than or equal to 3 times the ULN (5 times the ULN if liver metastases are present), and creatinine clearance greater than or equal to 50 mL/min.
- Agreement to use contraception according to the protocol.
Exclusion Criteria:
- Pregnant, breast-feeding, or planning to become pregnant during the study.
- Any investigational medicinal product within 30 days, before Cycle 1 Day 1.
- Part 1 only: more than 4 prior lines of systemic chemotherapy in the advanced or metastatic setting. Part 2 instead applies tumour-type-specific requirements for prior lines of therapy.
- Uncontrolled brain metastases.
- Active or past autoimmune disease or immunodeficiency.
- Idiopathic pulmonary fibrosis, organising pneumonia, drug-induced or idiopathic pneumonia, or evidence of active pneumonia at screening.
- Severe cardiovascular disease within 6 months.
- Significant surgical procedures, other than diagnostic surgery, within 4 weeks before the start of study treatment, or expected to require significant surgery during the study period.
- Known human immunodeficiency virus infection or current active hepatitis B or hepatitis C. Participants with prior HBV infection with negative HBV DNA are eligible. Participants clinically cured of hepatitis C, at least 12 weeks after completing antiviral treatment, are eligible.
- History of life-threatening toxicity related to prior immune therapy, for example an inhibitor of PD-1 or PD-L1, an anti-CTLA-4 agent, or any other drug targeting T-cell activation or immune checkpoint pathways.
- A live virus vaccine within the 4 weeks before Cycle 1 Day 1, or plans to receive a live virus vaccine during the study.
- Corrected QT interval using Fridericia correction greater than 470 milliseconds.
- Prior treatment with DAX-044 or any interleukin-12-based agent.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Experimental: Part 1 - DAX-044 Monotherapy Dose Escalation
DAX-044 administered at ascending dose levels to participants with advanced solid tumours, to assess safety and tolerability and determine the maximum tolerated dose (MTD). Dose escalation follows a Bayesian optimal interval (BOIN) design. |
DAX-044 monotherapy |
|
Experimental: Part 2 - DAX-044 Monotherapy Dose Expansion in Tumour-Specific Cohorts
Part 2 will further evaluate the safety and anti-tumour activity of DAX-044 monotherapy, at dose levels selected from Part 1, in up to 4 tumour-specific expansion cohorts. |
DAX-044 monotherapy |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Prazo |
|---|---|
|
Number of Participants With Treatment-Emergent Adverse Events (TEAEs) as Assessed by CTCAE v6.0
Prazo: Up to 24 months
|
Up to 24 months
|
|
Maximum Tolerated Dose (MTD) of DAX-044 Based on Dose-Limiting Toxicities (DLTs) (Part 1)
Prazo: Up to 24 months
|
Up to 24 months
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Prazo |
|---|---|
|
Serum Concentrations of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Maximum Observed Serum Concentration (Cmax) of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Time to Maximum Observed Serum Concentration (Tmax) of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Trough Serum Concentration (Ctrough) of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Area Under the Serum Concentration Versus Time Curve Over the Dosing Interval (AUCtau) of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Terminal Half-Life (t1/2) of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Clearance (CL) of DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Number of Participants With Anti-Drug Antibodies (ADA) to DAX-044
Prazo: Up to 24 months
|
Up to 24 months
|
|
Objective Response Rate (ORR) as Assessed by the Investigator per RECIST 1.1
Prazo: Up to 24 months
|
Up to 24 months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Início do estudo
Conclusão Primária (Estimado)
Conclusão Primária
Conclusão do estudo (Estimado)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Outros números de identificação do estudo
Outros números de identificação do estudo
- DAX-044-2601
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .